Blonanserin: A review of its use in the management of schizophrenia

CNS Drugs

Volumn 24, Issue 1, 2010, Pages 65-84

  Deeks, Emma D ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Antipsychotics, general; Blonanserin, general; Schizophrenia

Indexed keywords

ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID; BLONANSERIN; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DIAZEPAM; DILTIAZEM; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ERYTHROMYCIN; HALOPERIDOL; KETOCONAZOLE; NEUROTRANSMITTER RECEPTOR; PHENYTOIN; PROLACTIN; PROTEINASE INHIBITOR; RIFAMPICIN; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; TRIAZOLAM; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

AKATHISIA; BRADYKINESIA; BRIEF PSYCHIATRIC RATING SCALE; CENTRAL NERVOUS SYSTEM; CLINICAL GLOBAL IMPRESSION SCALE; DRUG ALCOHOL INTERACTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FOOD DRUG INTERACTION; GAIT DISORDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; INSOMNIA; LIMBIC SYSTEM; LIPID BLOOD LEVEL; LONG TERM CARE; MALAISE; MENTAL DISEASE; MUSCLE RIGIDITY; PATIENT MONITORING; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RECEPTOR OCCUPANCY; REPEATED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; CLINICAL TRIAL; DRUG INTERACTION; PATHOPHYSIOLOGY; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; PIPERAZINES; PIPERIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77649268156     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11202620-000000000-00000     Document Type: Review

References (29)

1. World Health Organization. The world health report 2001 [online]. Available from URL: http://www.who.int/whr/2001/en/whr01-en.pdf [Accessed 2009 May 1]
2. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update) [online]. Available from URL: http://nice.org.uk/ nicemedia/pdf/CG82FullGuideline.pdf [Accessed 2009 Jun 4]
3. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6 (3): 132-91
4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia: second edition [online]. Available from URL: http://www.psychiatryonline. com/pracGuide/loadGuidelinePdf.aspx?file= Schizophrenia2e-Inactivated-04-16-09 [Accessed 2009 Jun 8]
5. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009 Jan 3; 373 (9657): 31-41
6. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21 (11): 911-36 (Pubitemid 47557106)
7. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia. Drugs 2008; 68 (16): 2269-92
8. Lonansen® (Blonanserin): prescribing information. Osaka: Dainippon Sumitomo Pharma Co. Ltd, 2009 Jan
9. Korea Food and Drug Administration. Ronasenjeong [online]. Available from URL: http://ezdrug.kfda.go.kr [Accessed 2009 Nov 25]
10. Murasaki M. Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol [English abstract]. Jpn J Clin Psychopharmacol 2007; 10: 2059-79
11. Miura S. Clinical evaluation of blonanserin for schizophrenia: a randomized study comparing blonanserin with risperidone [English abstract]. Jpn J Clin Psychopharmacol 2008; 11: 297-314
12. Oka T, Hamamura T, Lee Y, et al. Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. Life Sci 2004 Nov 26; 76 (2): 225-37 (Pubitemid 39425227)
13. Oka M, Noda Y, Ochi Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 1993 Jan; 264 (1): 158-65 (Pubitemid 23309197)
14. Noda Y, Kurumiya S, Miura Y, et al. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9,10-hex ahydrocycloocta[b] pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther 1993 May; 265 (2): 745-51
15. Nagai T, Noda Y, Une T, et al. Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioural changes in mice. Neuroreport 2003 Feb 10; 14 (2): 269-72 (Pubitemid 36308425)
16. - current in rat dorsal root ganglion neurons: differences between some neuroleptics. Br J Pharmacol 2002 Mar; 135 (6): 1547-55
17. Investigator's brochure. Osaka: Dainippon Sumitomo Pharma Co. Ltd, 2006 Feb. (Data on file)
18. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60 Suppl. 10: 5-14 (Pubitemid 29237170)
19. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994 Nov; 271 (2): 1058-66 (Pubitemid 24377799)
20. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64 (20): 2291-314 (Pubitemid 39388605)
21. American Diabetes Association; American Association of Clinical Endocrinologists; American Psychiatric Association; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004 Feb; 65 (2): 267-72
22. Suzuki H, Morokawa Y, Gen K, et al. The relationship between the daily dose, the plasma concentration of AD-5423 (blonanserin), and its plasma anti-dopamine (D2) and anti-serotonin (5-HT2A) activity, and the plasma serotonin/dopamine (S/D) ratio [abstract]. Int Clin Psychopharmacol 2003 May; 18: 187
23. Murasaki M. Phase II study results of AD-5423, a newly synthesized SDA neuroleptic in Japan. Psychopharmacol Bull 1997; 33 (3): 560
24. Garcia E, Robert M, Peris F, et al. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.CNS Drugs 2009; 23 (7): 615-25
25. Miyake N, Miyamoto S, Takeuchi A, et al. Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: a randomized double-blind comparison with risperidone [English abstract]. Jpn J Clin Psychopharmacol 2008; 11: 315-26
26. Kinoshita T. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japan-wide study) [English abstract]. Jpn J Clin Psychopharmacol 2008; 11: 135-53
27. Murasaki M. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group) [English abstract]. Jpn J Clin Psychopharmacol 2007; 10: 2241-57
28. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003 Nov; 64 (11): 1308-15 (Pubitemid 37490235)
29. Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv 2008 Oct; 59 (10): 1207-10